Tags

Type your tag names separated by a space and hit enter

Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.
Int J Geriatr Psychiatry 1998; 13(11):767-74IJ

Abstract

To better define the influence of apolipoprotein E (ApoE) epsilon 4 genotype on the cognitive and biochemical features of Alzheimer's disease (AD), cross-sectional analysis of global cognitive measures and cerebrospinal fluid studies gathered on AD subjects at a tertiary care facility between 1986 and 1997 was carried out. The 112 AD patients examined included 62 women and 50 men with a mean (SD) age of 64.2 (9.2) years. Patient demographics; illness onset age and duration, education level and global cognitive measures were recorded systematically. Genetic analysis for ApoE allele type and biochemical characterization of CSF, including total tau concentration, was performed. Descriptive statistics of demographics, cognitive and CSF measures were performed by chi-square, ANOVA and Tukey's tests. Overrepresentation of the epsilon 4 allele was found, with 45.5% of AD patients heterozygous and 20.5% homozygous for ApoE epsilon 4. Overall, ApoE epsilon 4 status had no effect on mean onset age of AD (F = 1.56; p = 0.214), but an earlier mean onset age of AD (F = 4.10; p = 0.02) was seen in the late-onset subjects. No differences were found with regard to ApoE epsilon 4 status and measures of disease, duration of illness or global cognitive performance. Although CSF tau was elevated in our sample (575.4 +/- 290.3 pg/ml), ApoE epsilon 4 status did not influence total CSF tau or neurotransmitter metabolite levels. ApoE epsilon 4 genotype had no impact on a variety of illness severity, cognitive and CSF examinations in the largest cross-sectional analysis of AD subjects yet reported.

Authors+Show Affiliations

Geriatric Psychiatry Branch, National Institute of Mental Health, Bethesda, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9850873

Citation

Lasser, R A., et al. "Apolipoprotein E Epsilon 4 Allele in Association With Global Cognitive Performance and CSF Markers in Alzheimer's Disease." International Journal of Geriatric Psychiatry, vol. 13, no. 11, 1998, pp. 767-74.
Lasser RA, Dukoff R, Levy J, et al. Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease. Int J Geriatr Psychiatry. 1998;13(11):767-74.
Lasser, R. A., Dukoff, R., Levy, J., Levin, R., Lehtimäki, T., Seubert, P., & Sunderland, T. (1998). Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease. International Journal of Geriatric Psychiatry, 13(11), pp. 767-74.
Lasser RA, et al. Apolipoprotein E Epsilon 4 Allele in Association With Global Cognitive Performance and CSF Markers in Alzheimer's Disease. Int J Geriatr Psychiatry. 1998;13(11):767-74. PubMed PMID: 9850873.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease. AU - Lasser,R A, AU - Dukoff,R, AU - Levy,J, AU - Levin,R, AU - Lehtimäki,T, AU - Seubert,P, AU - Sunderland,T, PY - 1998/12/16/pubmed PY - 2000/6/20/medline PY - 1998/12/16/entrez SP - 767 EP - 74 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 13 IS - 11 N2 - To better define the influence of apolipoprotein E (ApoE) epsilon 4 genotype on the cognitive and biochemical features of Alzheimer's disease (AD), cross-sectional analysis of global cognitive measures and cerebrospinal fluid studies gathered on AD subjects at a tertiary care facility between 1986 and 1997 was carried out. The 112 AD patients examined included 62 women and 50 men with a mean (SD) age of 64.2 (9.2) years. Patient demographics; illness onset age and duration, education level and global cognitive measures were recorded systematically. Genetic analysis for ApoE allele type and biochemical characterization of CSF, including total tau concentration, was performed. Descriptive statistics of demographics, cognitive and CSF measures were performed by chi-square, ANOVA and Tukey's tests. Overrepresentation of the epsilon 4 allele was found, with 45.5% of AD patients heterozygous and 20.5% homozygous for ApoE epsilon 4. Overall, ApoE epsilon 4 status had no effect on mean onset age of AD (F = 1.56; p = 0.214), but an earlier mean onset age of AD (F = 4.10; p = 0.02) was seen in the late-onset subjects. No differences were found with regard to ApoE epsilon 4 status and measures of disease, duration of illness or global cognitive performance. Although CSF tau was elevated in our sample (575.4 +/- 290.3 pg/ml), ApoE epsilon 4 status did not influence total CSF tau or neurotransmitter metabolite levels. ApoE epsilon 4 genotype had no impact on a variety of illness severity, cognitive and CSF examinations in the largest cross-sectional analysis of AD subjects yet reported. SN - 0885-6230 UR - https://www.unboundmedicine.com/medline/citation/9850873/Apolipoprotein_E_epsilon_4_allele_in_association_with_global_cognitive_performance_and_CSF_markers_in_Alzheimer's_disease_ L2 - https://medlineplus.gov/alzheimersdisease.html DB - PRIME DP - Unbound Medicine ER -